1.02
-0.02 (-1.92%)
| Previous Close | 1.04 |
| Open | 1.07 |
| Volume | 40,429 |
| Avg. Volume (3M) | 129,075 |
| Market Cap | 7,311,075 |
| Price / Earnings (TTM) | 2.83 |
| Price / Book | 0.340 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -1.12 |
| Total Debt/Equity (MRQ) | 64.46% |
| Current Ratio (MRQ) | 2.12 |
| Operating Cash Flow (TTM) | -22.99 M |
| Levered Free Cash Flow (TTM) | -15.51 M |
| Return on Assets (TTM) | -111.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Calidi Biotherapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.00 |
|
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 5.43% |
| % Held by Institutions | 15.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rs Crum Inc. | 30 Sep 2025 | 15,256 |
| Grassi Investment Management | 30 Jun 2025 | 833 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |